Biotech entity
All 1 tracked stories fall under one category: clinical-trial. CMND-100 is most often covered alongside Clearmind Medicine Inc., which appears in 1 of these 1 story. CMND-100 appears in 1 tracked Biotech story from July 11, 2026. The tracked stories average 4 original sources each.
Last mentioned: Jul 11, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: clinical-trial. CMND-100 is most often covered alongside Clearmind Medicine Inc., which appears in 1 of these 1 story. CMND-100 appears in 1 tracked Biotech story from July 11, 2026. The tracked stories average 4 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 9 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering CMND-100. Shared-story counts are live from our verified record — not editorial picks.
Clearmind Medicine submitted a response to an HHS RFI highlighting its clinical-stage candidate CMND-100, an MEAI-based neuroplastogen for Alcohol Use Disorder. The drug engages 5-HT1A pathways without hallucinogenic effects, offering a novel mechanism for addiction treatment.
Source: Nynewscast · Financialcontent
CMND-100 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
